Genmab — August 2020
-
De omtaler ikke den okulare toksicitet https://haematologisktidsskrift.dk/sygdomme/myeloma/739-dansk-optimisme-efter-ema-godkendelse-af-ny-myelomatose-behandling.html
-
Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs https://investors.immatics.com/news-releases/news-release-details/immatics-announces-european-clinical-expansion-its-adoptive-cell
-
Immatics’ clinical product class ACTengine
is a personalized approach for patients with advanced solid cancers. Patient’s own T cells are genetically modified to express a novel proprietary TCR cognate to one of Immatics’ cancer targets identified by its proprietary XPRESIDENT target discovery platform. -
No news yet from ADCT "Announced FDA lifted partial clinical hold on pivotal Phase 2 trial of Cami for relapsed or refractory Hodgkin lymphoma: In July 2020, the Company announced that the FDA had lifted the partial clinical hold on its pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami, formerly ADCT-301) in patients with relapsed or refractory Hodgkin lymphoma (HL).
-
The Company continued to treat those patients who could benefit from ongoing treatment during the partial clinical hold, and the clinical trial is now open for enrollment. Interim results from the clinical trial are expected in the first half of 2021, subject to any impact by COVID-19. The clinical trial is intended to support the submission of a BLA to the FDA."
-
That would be nice:-)
-
dough
@semodough
$ADCT catalysts from Cami in 2H
ADCT is planning to present at two medical conferences in 2H. We expect PK/PD data of Cami in solid tumors at ESMO in Sept. Interim pivotal ph 2 catcHLight data (n=47) of Cami in Hodgkin's lymphoma (HL) would be at ASH (Dec. 5th-8th). -
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company AnnouncementCopenhagen, Denmark; August 18, 2020 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 62,716 shares as a consequence of the exercise of employee warrants.
The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:
-
400 shares at DKK 31.75,
6,500 shares at DKK 40.41,
1,500 shares at DKK 67.50,
47,438 shares at DKK 225.90,
50 shares at DKK 231.50,
850 shares at DKK 337.40,
2,000 shares at DKK 466.20,
275 shares at DKK 623.50,
250 shares at DKK 636.50,
1,175 shares at DKK 815.50,
1,150 shares at DKK 939.50, and
1,128 shares at DKK 1,145.00. -
Artikel om epcoritamab fra Rigshospitalets hjemmeside (samme tema som fra BT) https://www.rigshospitalet.dk/presse-og-nyt/nyheder/nyheder/Sider/2020/august/banebrydende-antistofbehandling-for-lymfekraeft-vinder-frem.aspx
derfor mit ?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind